Viking Therapeutics’ shares plunged 42% in a single session after mid-stage trial results but have seen renewed interest with ACT Capital’s $7.25M position and anticipation of a near-term catalyst from an upcoming maintenance study.

Revenue accelerated 28% year-over-year through a jump in capacity, Viking has completed enrollment in both the subcutaneous and oral Phase 3 VK2735 trials and plans to start the oral trial in Q3 2026, and cash on hand declined from $903 million to $706 million at year-end 2025.

River cruise operations have hedged roughly half their fuel needs and maintain fuel cost exposure at just 3–4.5% of revenue and OPEX, below peer levels, while high-net-worth and retiree demand outstrips industry supply, supporting pricing leverage. Viking Therapeutics’ VK2735 obesity candidate is advancing toward simultaneous oral and subcutaneous phase III trials in Q3 2026 with completed bioequivalence and planned autoinjector formats, subject to hepatic safety restrictions, and its VK2809 NASH therapy met primary and secondary endpoints in a Phase 2b study.

Investor enthusiasm centers on Viking’s GLP-1/GIP obesity candidate, with bullish narratives highlighting maintenance trial importance, high price targets, and CEO credibility, while some caution persists around near-term losses and hold ratings.

—

VKTX is advancing its oral obesity candidate VK2735 into Phase 3 in Q3 2026, supported by ahead-of-schedule enrollment in both Vanquish studies, an IND filing expected in Q1 2026, and a strong ~$700 M cash runway, even as R&D spend surges and net losses widen due to late-stage trial costs.

—

Announcements of Phase 3 advancement and rapid enrollment have fostered bullish narratives around the obesity program, though skepticism persists over high R&D losses, study requirements, and stretched valuation versus peers.

Insider selling of 57,661 shares coincided with a 16% drop in the last 30 days and a 22% decline over one year, marking a pullback after strong three-year momentum.

VK2735 achieved 14.7% weight loss in Phase 2 and has progressed into two global Phase 3 VANQUISH trials, with VANQUISH-1 enrollment complete and VANQUISH-2 nearing completion, while maintenance dosing studies and exploration of an oral formulation continue.

No marketed therapies mean no near-term revenues, while a burgeoning pipeline of GLP-1–based and dual agonist candidates awaits IND clearance amid stiff competition from pharma incumbents.

Buy-side enthusiasm for VKTX’s VK2735 trials is high, as analysts rate it a strong buy with upside targets near +175–196%, but investors remain wary of persistent losses, sell ratings, and mixed oral study data as they await upcoming earnings and regulatory milestones.